State Key Laboratory of Experimental Hematology (SKLEH), funded by the State Planning Commission and established in 1988, became operational in 1991. The lab is affiliated with Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. Leveraging the synergies of basic science and clinical researches, SKLEH focuses on the research and treatment for hematological diseases in China. Taking hematopoietic stem cell biology as the main entry point with particular emphasis on pathogenesis of hematologic malignancies, the lab looks for normal and pathological hematopoietic stem cells and molecular targets for intervention in morbid hematopoietic microenvironment. The primary mission of SKLEH is to lead cutting edge researches and treatment practice in the field of hematology and to provide scientific basis of new clinical treatment strategies for various hematological disorders.
In the past five years, SKLEH has undertaken a total of 234 various research projects, including 28 projects from the Ministry of Science and Technology, 76 projects from the National Natural Science Foundation, and 130 from other ministries and local governments. SKLEH also published 668 papers, of which nearly 300 papers were published in SCI, includingNatuer, Nat Genetics, Blood, Leukemia, Cell Researchand others, winning the National Science and Technology Progress Award, and 11 provincial science and technology awards. In a course of 5 years, SKLEH provides educational programs that produce 62 graduate and 121 doctoral students.
SKLEH, covering an area of 7400 square meters, has five major technology-sharing platforms that fully demonstrate the functions of a state key laboratory in public support and international scholarly communication and exchanges.